深圳市理邦精密仪器股份有限公司 独立董事对第五届董事会2023年第三次会议相关事项的独立意见 根据《中华人民共和国公司法》、《中华人民共和国证券法》、《上市公司 独立董事规则》、《深圳证券交易所创业板股票上市规则》、《深圳证券交易所 上市公司自律监管指引第2号——创业板上市公司规范运作》、《深圳市理邦精 密仪器股份有限公司章程》等相关规定，我们作为公司的独立董事，对公司相关 事项发表如下独立意见如下： 一、关于控股股东、实际控制人及其他关联方占用公司资金情况的独立意见 经核查，报告期内，公司不存在控股股东、实际控制人及其他关联方违规占 用公司资金的情况，也不存在以前年度发生并延续至2023年6月30日的违规关联 方资金占用情况。公司与其他关联方的资金往来符合规范性要求。 经核查，报告期内，公司不存在为控股股东及其他关联方提供担保的情形， 也不存在任何违规对外担保事项。公司严格遵守《公司法》、《深圳证券交易所 上市公司自律监管指引第2号——创业板上市公司规范运作》等相关规定，严格 控制相关风险。 三、关于公司会计政策变更的独立意见 公司依照财政部的要求，对公司会计政策相应变更，符合财政部、中国证监 会和深圳证券 ...

深圳市理邦精密仪器股份有限公司 证券代码：300206 证券简称：理邦仪器 公告编号：2023-024 深圳市理邦精密仪器股份有限公司 关于公司会计政策变更的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 深圳市理邦精密仪器股份有限公司（以下简称"公司"）根据财政部于 2022 年颁布的《关于印发<企业会计准则解释第 16 号>的通知》的要求变更公司会计 政策。现将具体情况公告如下： 一、本次会计政策变更的概述 本次会计政策变更前，公司执行财政部发布的《企业会计准则—基本准则》 和各项具体会计准则、企业会计准则应用指南、企业会计准则解释公告以及其他 相关规定。 4、变更后采用的会计政策 本次会计政策变更后，公司将执行财政部发布的解释第 16 号。除上述会计 政策变更外，其余未变更部分，仍执行财政部颁布的《企业会计准则—基本准则》 和各项具体会计准则、企业会计准则应用指南、企业会计准则解释公告及其他相 关规定。 1、变更原因 2022 年 11 月 30 日，财政部颁布了《关于印发<企业会计准则解释第 16 号> 的通知》（财会〔2022〕31 号）(以下 ...

深圳市理邦精密仪器股份有限公司 2023 年半年度非经营性资金占用及其他关联资金往来情况汇总表 编制单位：深圳市理邦精密仪器股份有限公司 单位：人民币万元 | | | | | | | 2023 年度 | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 非经营性资 | | 占用方与上 | 上市公司核 | 2023 | 年期初 | 占用累计 | 2023 年度占 | 2023 年度 | 2023 年期 | 占用形 | | | 金占用 | 资金占用方名称 | 市公司的关 | 算的会计科 | | 占用资金余 | 发生金额 | 用资金的利 | 偿还累计 | 末占用资 | 成原因 | 占用性质 | | | | 联关系 | 目 | | 额 | （不含利 | 息（如有） | 发生金额 | 金余额 | | | | | | | | | | 息） | | | | | | | 控股股东、实 | | | | | | | | | | | | | 际 控 制 人 及 | | | | | | | | | | | 非经营 ...

Financial Performance - The company's revenue for Q1 2023 reached ¥639,691,149.30, representing a 64.21% increase compared to ¥389,562,418.35 in the same period last year[5] - Net profit attributable to shareholders was ¥140,419,036.49, a significant increase of 183.36% from ¥49,554,550.08 year-on-year[5] - The net profit after deducting non-recurring gains and losses was ¥136,629,365.90, up 312.28% from ¥33,140,110.56 in the previous year[5] - Basic earnings per share rose to ¥0.2423, reflecting an increase of 184.39% compared to ¥0.0852 in the same period last year[5] - The total comprehensive income for the current period is 139,918,904.24, compared to 49,015,698.20 in the previous period, reflecting a substantial increase[41] Assets and Liabilities - The company's total assets at the end of the reporting period were ¥2,317,584,767.18, a 3.67% increase from ¥2,235,526,845.67 at the end of the previous year[5] - Cash and cash equivalents at the end of Q1 2023 were CNY 981,762,562.67, an increase from CNY 957,004,450.27 at the beginning of the year[34] - Total assets as of March 31, 2023, were CNY 2,317,584,767.18, up from CNY 2,235,526,845.67 at the start of the year[36] - The company reported a total equity attributable to shareholders of CNY 1,992,512,134.96, an increase from CNY 1,853,056,782.31 at the beginning of the year[39] - The company’s total liabilities were CNY 1,326,346,755.57, compared to CNY 1,235,207,738.30 at the start of the year, indicating an increase in leverage[36] Cash Flow - Cash flow from operating activities increased by 46.97% to ¥36,627,250.07, compared to ¥24,921,223.37 in the same period last year[27] - Cash flow from operating activities is 36,627,250.07, compared to 24,921,223.37 in the previous period, showing an increase of about 47%[44] - The company reported a net cash outflow from investing activities of -9,051,968.36, compared to -107,849,571.75 in the previous period, showing an improvement[45] Operating Costs and Expenses - The company reported a 54.24% increase in operating costs, amounting to ¥269,126,826.78, up from ¥174,487,702.42 year-on-year[16] - The total operating costs for Q1 2023 amounted to CNY 504,390,307.61, up 39.7% from CNY 360,751,722.89 in Q1 2022[39] - Research and development expenses reached CNY 78,597,376.46, representing a 25% increase from CNY 62,947,222.23 in the previous year[39] - The company experienced a 118.31% increase in taxes and surcharges, totaling ¥6,822,216.53, compared to ¥3,124,955.41 in the previous year[16] - The company reported a decrease in other comprehensive income attributable to the parent company, with a net amount of -963,683.84 compared to 76,890.64 in the previous period[41] Sales and Revenue - The company received cash from sales of goods and services totaling 611,111,486.96, compared to 421,819,000.18 in the previous period, reflecting a growth of about 45%[44]

Financial Performance - The company's operating revenue for 2022 was CNY 1,742,412,298.64, representing a 6.48% increase compared to CNY 1,636,411,042.84 in 2021[31]. - The net profit attributable to shareholders for 2022 was CNY 232,987,942.35, a slight increase of 0.67% from CNY 231,436,439.33 in 2021[31]. - The cash flow from operating activities increased by 41.25% to CNY 335,157,849.02 in 2022, up from CNY 237,283,290.14 in 2021[31]. - The basic earnings per share for 2022 was CNY 0.4020, reflecting a 0.75% increase from CNY 0.3990 in 2021[31]. - Total assets at the end of 2022 amounted to CNY 2,235,526,845.67, a 9.15% increase from CNY 2,048,108,342.70 at the end of 2021[31]. - The company achieved operating revenue of 1,742.41 million yuan, a year-on-year increase of 6.48%[88]. - Net profit attributable to shareholders was 232.99 million yuan, up 0.67% year-on-year, while the net profit excluding non-recurring gains and losses was 200.92 million yuan, an increase of 4.94%[88]. - The gross margin improved to 45% in 2022, up from 40% in 2021, reflecting better cost management and pricing strategies[169]. - The company reported a significant increase in revenue, achieving a total of 1.5 billion RMB for the fiscal year 2022, representing a 20% year-over-year growth[169]. Product Development and Innovation - In 2022, the company launched several strategic new products, including the iX series monitors and i20 blood gas analyzers, enhancing its product portfolio[7]. - The company has established a diversified business layout across six major sectors: patient monitoring, ECG diagnosis, maternal and child health, ultrasound imaging, in vitro diagnostics, and smart healthcare[51]. - The company aims to leverage its innovative capabilities and global marketing network to provide comprehensive solutions for healthcare institutions[50]. - The company has developed advanced monitoring modules for its self-developed plug-in monitoring devices, including EtCO2, anesthesia, muscle relaxant, and EEG modules, achieving core technology import substitution[56]. - The company’s continuous non-invasive blood pressure measurement technology, CNBP, is a pioneering innovation in the industry, enhancing data monitoring and user experience[56]. - The company launched several new products in 2022, including the F12 next-generation fetal monitor and the iX series new generation monitor[139]. - The company launched several new products, including the CL30 fully automated nucleic acid detection analyzer and various related testing kits, enhancing its product relevance and competitive edge in the molecular diagnostics field[141]. - The introduction of a fetal and maternal monitor demonstrates the company's expansion into maternal health monitoring technologies[154]. - The company is actively pursuing innovation in medical technology, as evidenced by its ongoing registration efforts for new devices and updates to existing products[156]. Market Expansion and Global Presence - The company expanded its international presence by establishing subsidiaries in Kenya and Thailand, further developing its global marketing channels[7]. - The company aims to strengthen localization in international markets, ensuring high-quality equipment and localized after-sales service[10]. - The company has established a comprehensive after-sales service system covering over 170 countries and regions, providing 24/7 support[97]. - The company has integrated its domestic and international marketing teams, significantly improving global marketing efficiency[96]. - The company plans to continue strengthening its global marketing network to support future product expansion and market share growth[96]. - The company is expanding its market presence in Southeast Asia, targeting a 25% increase in market share by the end of 2023[179]. Research and Development - R&D investment for the reporting period was CNY 297.54 million, an increase of 17.95% year-on-year, accounting for 17.08% of the total revenue[93]. - The number of R&D personnel increased by 14.66% to 743 in 2022, with a notable rise in the proportion of staff holding bachelor's and master's degrees[143]. - The company is investing 200 million RMB in R&D for new monitoring technologies over the next three years[162]. - The company is investing in R&D for advanced diagnostic ultrasound systems, with a budget allocation of 100 million RMB for the next fiscal year[179]. Regulatory Approvals and Compliance - The company is currently in the registration process for multiple medical devices, including an ECG analysis software and patient monitors, with the ECG software classified as Class III and under technical review[146]. - The company has obtained NMPA registration for multiple ECG devices, including single-channel and multi-channel ECG machines, with registration dates ranging from April 2020 to June 2022, and expiration dates extending to 2025[156]. - The company is actively pursuing regulatory approvals for new products, which reflects its commitment to enhancing its medical device portfolio and market presence[149]. - The registration process for these devices is crucial for the company's growth strategy, as it aims to meet the increasing demand for advanced medical monitoring solutions[149]. Customer Engagement and Service - The company has established a strong online academic platform, hosting over 600 training sessions and attracting more than 200,000 healthcare professionals, enhancing its brand influence[111]. - The company provided health management and telemedicine services to over 300 medical institutions, completing more than 2 million ECG diagnostic services and over 1 million maternal and child health management services[120]. - The company has set up over 30 training bases for dynamic electrocardiogram training across the country, enhancing customer service capabilities[98]. Strategic Acquisitions - A strategic acquisition of a local competitor is anticipated to enhance the company's product portfolio and increase market penetration, expected to close by Q3 2023[170]. - The company completed a strategic acquisition of a competitor, which is anticipated to increase market share by 5%[200]. Future Outlook - The company provided a positive outlook for 2023, projecting a revenue growth of 15% to 1.725 billion RMB, driven by new product launches and market expansion strategies[169]. - The company has set a future outlook with a revenue guidance of 1.5 billion RMB for the next fiscal year, indicating a projected growth of 25%[162].

深圳市理邦精密仪器股份有限公司 投资者依据提示，授权登入"理邦仪器投资者关系"小程序，即可参与交流。 出席本次年度业绩说明会的人员有：公司董事长、总裁张浩先生，副总裁、 董事会秘书、财务负责人祖幼冬先生，财务执行总监林静媛女士，独立董事苏洋 先生。 1 证券代码：300206 证券简称：理邦仪器 公告编号：2023-005 深圳市理邦精密仪器股份有限公司 关于举行2022年度网上业绩说明会并征集相关问题的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 深圳市理邦精密仪器股份有限公司（以下简称"公司"）将于2023年4月7 日（星期五）下午15:00至17:00，在"理邦仪器投资者关系"小程序举行2022 年度网上业绩说明会，本次网上业绩说明会将采用网络远程的方式举行，投资 者可登陆"理邦仪器投资者关系"小程序参与互动交流。 参与方式一：在微信中搜索"理邦仪器投资者关系"； 参与方式二：微信扫一扫以下二维码： 深圳市理邦精密仪器股份有限公司 为进一步做好中小投资者保护工作，增进投资者对公司的了解和认同，以提 升公司治理水平和企业整体价值，现就公司2022年 ...